Login to Your Account



Data snafu aside, Xilonix meets endpoint; EMA filing up next

By Marie Powers
News Editor

Monday, December 7, 2015

Ten days after disappointing investors in what appeared a messy mistake in the European phase III trial of Xilonix in symptomatic, advanced colorectal cancer, Xbiotech Inc. turned its story around.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription